Literature DB >> 22614634

Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments.

Holger Dette1, Andrey Pepelyshev, Weng Kee Wong.   

Abstract

We consider two frequently used PK/PD models and provide closed form descriptions of locally optimal designs for estimating individual parameters. In a novel way, we use these optimal designs and construct locally standardized maximin optimal designs for estimating any subset of the model parameters of interest. We do this by maximizing the minimal efficiency of the estimates across all relevant parameters so that these optimal designs are less dependent on the individual parameter or parameters of interest. Additionally, robust designs are proposed to further reduce the dependence on the nominal values of the parameters. We compare efficiencies of our proposed optimal designs with locally optimal designs and designs used in four real studies from the literature and show that our proposed designs provide advantages over those used in practice.

Entities:  

Mesh:

Year:  2012        PMID: 22614634      PMCID: PMC4284081          DOI: 10.1007/s10928-012-9251-7

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  16 in total

1.  An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-09-07       Impact factor: 15.470

2.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

3.  Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression.

Authors:  Hervé Le Nagard; Corine Vincent; France Mentré; Jacques Le Bras
Journal:  Comput Methods Programs Biomed       Date:  2010-09-09       Impact factor: 5.428

4.  Methods of robust design of nonlinear models with an application to pharmacokinetics.

Authors:  Lee-Kien Foo; Stephen Duffull
Journal:  J Biopharm Stat       Date:  2010-07       Impact factor: 1.051

5.  A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models.

Authors:  Ivelina Gueorguieva; Kayode Ogungbenro; Gordon Graham; Sophie Glatt; Leon Aarons
Journal:  Comput Methods Programs Biomed       Date:  2007-02-09       Impact factor: 5.428

6.  Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.

Authors:  Caroline Bazzoli; Sylvie Retout; France Mentré
Journal:  Comput Methods Programs Biomed       Date:  2009-11-04       Impact factor: 5.428

7.  Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-06-10       Impact factor: 2.745

8.  Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.

Authors:  Franziska Schädeli; Hans-Peter Marti; Felix J Frey; Dominik E Uehlinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation.

Authors:  Mindy He Magee; Robert A Blum; Christian D Lates; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

10.  Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice.

Authors:  H A El-Masri; C J Portier
Journal:  Drug Metab Dispos       Date:  1998-06       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.